Day: January 20, 2022

To NASDAQ Copenhagen A/S   Executive Board Lersø Parkalle 100 DK-2100 København Ø www.rd.dk Telephone +45 7012 5300 20 January 2022Company Announcement number 6/2022 Fixing of interest rate and refinancing triggersRealkredit Danmark hereby publishes interest rate and refinancing triggers. The interest rate and refinancing triggers are set out in the appendix to this announcement and is available on www.rd.dk/investor.   The Executive Board   Any additional questions should be addressed to Chief Analyst Hella Gebhardt Rønnebæk, phone +45 45 13 20 68.AttachmentsNr. 6_Fastsaettelse af triggerrenter_ukBilag til selskabsmeddelelse nr. 6-2022_uk

ORION CORPORATION PRESS RELEASE 20 January 2022 at 14.30 EET          Orion publishes Financial Statement Release for 2021 on Thursday 10 February 2022 Orion will publish Financial Statement Release for 2021 on Thursday, 10 February 2022 at approximately 12.00 noon EET. The release and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing. Webcast and conference call A webcast and a conference call for analysts, investors and media will be held on Thursday, 10 February 2022 at 13.30 EET. The event will be held only online and by conference call. A link to the live webcast will be available on Orion’s website at www.orion.fi/en/investors. A recording of the event will be available on the website later the same day. To participate the conference call, please dial: Finland:...

Company announcement – No. 3 / 2022 Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel SyndromeFull trial results of EASE-SBS 1 expected in the third quarter of 2022 Pending positive pivotal data, Zealand intends to file for marketing approval with the U.S. Food and Drug AdministrationCopenhagen, DK and Boston, MA, U.S. January   20, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced completion of patient enrollment in its pivotal Phase 3 trial (EASE-SBS 1) of glepaglutide, the company’s long-acting GLP-2 analog, for the potential treatment of short bowel syndrome (SBS). Glepaglutide is being investigated for once or twice...

Integrates all boating and navigation functions into one sharp and bright touch display MONTREAL, Jan. 20, 2022 (GLOBE NEWSWIRE) — Vision Marine Technologies, Inc. (NASDAQ: VMAR) (“Vision Marine” or the “Company”), the global leader in the electric transition of the recreational boating industry serving both OEMs and consumers, has partnered with Nextfour Solutions Ltd. (Nextfour) to further develop a customized multifunctional display to be integrated within Vision Marine’s groundbreaking E-Motion™ 180 fully electric powertrain system. The Q Display is the first marine display that brings the familiar automotive-like user experience to boating by integrating the on-board computer, mobile connectivity, chart plotter, guard, and entertainment system in one single device. This smart navigation device, which is called the Q Experience,...

WALTHAM, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the first patient has been dosed in the company’s Phase 1/2 clinical trial evaluating XTX202 for the treatment of solid tumors. XTX202 is a modified form of IL-2 that is designed to localize activity in the tumor microenvironment (TME), with the goal of overcoming the known tolerability challenges of existing IL-2 therapies while achieving enhanced anti-tumor activity. “We are pleased to begin patient dosing in our Phase 1/2 clinical trial with XTX202, a novel tumor selective IL-2 candidate with the potential to increase the therapeutic benefit of IL-2,” said Marty Huber, M.D., president of research and development...

Table 2: 2019 Marimaca Oxide Deposit Mineral Resource Estimate**CuT means total copper and CuS means acid soluble copper. Mineral resources that are not mineral reserves do not have demonstrated economic viability. Does not include primary sulphides. Refer to news release “Coro Announces Substantial Increase in Resources; Development Studies Underway” 2 December 2019. Technical and economic parameters included: copper price US$3.00/lb; mining cost US$2.00/t; HL processing cost including G&A US$9.00/t; ROM processing cost including G&A US$2.50/t; selling cost US$0.07/lb; heap leach recovery 76% of CuT; ROM recovery 40% of CuT; pit slope angle 44-46°.Figure 1Plan view of exploratory scout drilling program overlain on rock geochemistryVANCOUVER, British Columbia, Jan. 20, 2022 (GLOBE NEWSWIRE)...

NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) — Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company’s Board of Directors. Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such as Keystone Dental (serving as Audit Committee Chair), Medical Facilities Corporation (serving as Audit and Investment Committee Chair), and Dynatronics Corporation (serving on the Audit, Compensation, Nominating and Governance Committees). She is currently managing partner and co-founder of Prettybrook Partners, LLC, an investment firm specializing...

DANVILLE, Va., Jan. 20, 2022 (GLOBE NEWSWIRE) — American National Bankshares Inc. (NASDAQ: AMNB) (“American National” or the “Company”) today reported fourth quarter 2021 earnings of $11.3 million, or $1.05 per diluted common share. Those results compare to $8.8 million, or $0.80 per diluted common share, during the same quarter in the prior year, and net income of $10.2 million, or $0.94 per diluted common share, recognized for the third quarter of 2021. Earnings for the twelve months ended December 31, 2021 were $43.5 million, or $4.00 per diluted common share, compared to $30.0 million, or $2.73 per diluted common share, for the same period of 2020. President and Chief Executive Officer, Jeffrey V. Haley, commented, “American National finished 2021 on a positive note with strong earnings for the fourth quarter and the full year....

CALGARY, Alberta, Jan. 20, 2022 (GLOBE NEWSWIRE) — (PIPE – TSX) Pipestone Energy Corp. (“Pipestone” or the “Company”) today announced it has achieved independent certification of all its production from its world class Pipestone Wembley asset under the Equitable Origin EO100™ Standard for Responsible Energy Development. The certified unit is in the Montney formation, located west of Grande Prairie, Alberta, covering more than 90,000 net acres. The company began the process of seeking independent certification through Equitable Origin in April 2021. The EO100™ Standard for Responsible Energy Development is a set of rigorous performance standards for energy development projects that was developed by the non-profit organization Equitable Origin. The EO100™ standard represents leading industry practices for site-level ESG performance...